Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PAAG vs AG in advanced metastatic pancreatic cancer
NCT06051851Phase 2Recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Jul 2023
- Primary completion
- Jul 2025
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of penpulimab and anlotinib in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Nanjing Drum-Tower Hospital. Primary endpoint: Progression-Free Survival at 1 year. Started Jul 2023; status: recruiting.
02
Drugs
penpulimabanlotinib
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06051851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06051851.